AlphaVax is pioneering a new class of vaccines through its proprietary alphavaccine technology, which utilizes an RNA replicon vector platform derived from the Venezuelan equine encephalitis (VEE) virus. This innovative approach is designed to enhance the immune response against both infectious diseases and cancer. The company has developed a portfolio of seven vaccine candidates, focusing on applications in cancer immunotherapy and infectious disease prevention. Notably, AlphaVax's technology has demonstrated a favorable safety profile in clinical trials, with candidates targeting diseases such as human cytomegalovirus, influenza, and HIV-1, as well as various cancers including colon and breast cancer.

The alphavaccine platform is particularly significant in cancer treatment, as it has shown the ability to "break self-tolerance" and elicit robust immune responses against tumor-associated antigens. Clinical trials have indicated promising results, such as improved survival rates in patients with advanced cancers and the induction of specific T-cell responses. AlphaVax's commitment to advancing its vaccine candidates through rigorous clinical testing underscores its potential to redefine the role of vaccines in modern medicine, particularly in the realms of cancer immunotherapy and infectious disease management.

United States

The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.

AlphaVax

Company Details